全球心臟病學和神經病學 IVD 市場

預計到 2030 年，全球心臟病學和神經病學 IVD 市場規模將達到 278 億美元

2024年，全球心臟病學和神經病學體外診斷器材市場規模估計為173億美元，預計到2030年將達到278億美元，2024年至2030年的複合年成長率為8.2%。本報告分析的細分市場之一－儀器市場，預期複合年成長率為9.8%，到分析期結束時規模將達到170億美元。試劑和耗材市場在分析期間的複合年成長率估計為5.8%。

美國市場規模估計為 47 億美元，中國市場預計複合年成長率為 13.1%

美國心臟病學和神經病學體外診斷 (IVD) 市場規模預計在 2024 年達到 47 億美元。作為世界第二大經濟體，中國預計到 2030 年市場規模將達到 61 億美元，在 2024-2030 年的分析期內，複合年成長率為 13.1%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為 4.0% 和 8.0%。在歐洲，預計德國的複合年成長率為 5.5%。

心臟病學和神經病學的體外診斷市場—關鍵趨勢和促進因素摘要

心臟病學和神經病學領域的體外診斷 (IVD) 技術正在快速發展，幫助實現早期疾病檢測、風險評估和個人化治療策略。心血管疾病和神經系統疾病是全球死亡和殘疾的主要原因，IVD 技術在改善患者預後方面發揮關鍵作用。基於生物標記的檢測、分子診斷、照護現場(POC) 和數位健康整合的進步正在推動該領域的創新。

隨著心臟病、中風、神經退化性疾病和認知障礙的發病率不斷上升，醫療保健提供者和研究人員越來越依賴體外診斷 (IVD) 解決方案來實現精準診斷、疾病監測和治療最佳化。對高靈敏度心臟和神經系統生物標記、人工智慧主導的診斷和快速檢測解決方案的需求正在推動市場成長並改變臨床決策。

科技進步如何增強心臟科的體外診斷？

心臟體外診斷領域取得了突破性進展，尤其是在高靈敏度檢測、照護現場心臟生物標記檢測和分子診斷方面。其中最重要的創新之一是高靈敏度心肌肌鈣蛋白 (hs-cTn) 檢測的開發，該檢測能夠早期發現心肌梗塞 (MI) 和急性冠狀動脈症候群(ACS)。這些超靈敏的檢測能夠檢測到心肌肌鈣蛋白水平的細微變化，從而實現早期療育，改善風險分層，並減少住院治療。

另一項重大進展是整合多種生物標記組合，用於心血管疾病風險評估。傳統上，血脂譜（低密度脂蛋白 (LDL)、高密度脂蛋白 (HDL)、總膽固醇、三酸甘油酯）一直是評估心血管健康狀況的標準。然而，現代體外診斷 (IVD) 解決方案融合了高敏感性 C 反應蛋白 (hs-CRP)、利鈉肽 (BNP/NT-proBNP) 和髓過氧化物酶 (MPO) 等生物標記物，從而提供全面的心血管風險洞察。這些先進的生物標記測量方法能夠制定個人化的預防策略，並實現早期心血管疾病 (CVD) 介入。

另一個重要趨勢是心臟標記照護現場檢測 (POC) 的擴展。如今，可攜式、快速、手持式 POC 分析儀可在急診室、救護車和初級保健機構即時檢測肌鈣蛋白、D-二聚體和腦鈉肽 (BNP)。這顯著改善了早期分流決策，縮短了周轉時間，並增強了院前心臟事件管理。此外，穿戴式生物感測器和遠端心臟監測設備的興起使得持續的心臟健康追蹤成為可能，從而促進了主動干預，並減少了因心臟衰竭和心律不整而住院的人數。

此外，遺傳性心血管疾病的分子和基因檢測正在改變疾病的預防和管理。遺傳性高膽固醇症(FH)、肥厚型心肌病(HCM) 和長QT症候群 (LQTS) 等疾病的基因篩檢正變得越來越普及，這使得早期識別高危險群並針對性地制定生活方式和藥物干預措施成為可能。基於人工智慧的心電圖解讀與數位病理學的融合也正在推動心血管疾病 (CVD) 的自動化診斷和預後。

推動神經病學 IVD 發展的市場趨勢是什麼？

受神經退化性疾病、中風和認知障礙日益加重的負擔所推動，神經診斷領域正在經歷快速變化。其中最重要的趨勢之一是開發阿茲海默症(AD) 和帕金森氏症 (PD) 的血液生物標記。傳統上， 阿茲海默症 的診斷依賴腦脊髓液 (CSF) 分析或 PET 影像，這兩種方法都具有侵入性且昂貴。然而，近年來，基於血漿的 BETA-澱粉樣蛋白（ABETA42/ABETA40 比率）、 Tau蛋白（pTau-181、pTau-217）和神經絲輕鏈 (NfL) 檢測方法的進展，使得對阿茲海默症和其他神經退化性疾病進行非侵入性且可擴展的篩檢成為可能。

另一個主要趨勢是神經病學中分子診斷技術的擴展，特別是針對神經發育障礙、癲癇和神經肌肉疾病的基因檢測。次世代定序儀(NGS) 和 CRISPR 技術在診斷方法上的進步，使得早期發現與肌萎縮側索硬化症 (ALS)、多發性硬化症 (MS) 和遺傳性共濟失調等疾病相關的基因突變成為可能。這些精準的診斷工具有助於個人化治療選擇、早期療育和標靶基因治療。

用於卒中診斷和管理的體外診斷 (IVD) 解決方案的興起也推動了市場的成長。傳統上，卒中診斷依賴神經影像學（CT、MRI），但神經膠質纖維酸性蛋白 (GFAP)、S100B 和 D-二聚體等卒中生物標記組合的引入，增強了卒中的早期發現以及缺血性卒中和出血性卒中的鑑別診斷。即時血液中風檢測 (POC) 正成為院前中風評估的顛覆性技術，能夠加快介入速度並改善患者預後。

此外，人工智慧神經診斷、數位生物標記和遠端監控的日益融合正在改變神經系統疾病的檢測和進展追蹤：人工智慧對腦電圖、核磁共振成像和語音模式的分析正在改善癲癇、失智症和運動障礙的診斷，而穿戴式神經技術則可以對帕金森氏症、多發性硬化症和中風後復健進行即時神經監測。

什麼因素推動了心臟病學和神經病學 IVD 的發展？

循環系統和神經系統體外診斷 (IVD) 市場正在不斷擴張，這得益於幾個關鍵的成長促進因素，包括心血管和神經退化性疾病患病率的上升、生物標記發現的進步以及對非侵入性診斷的需求不斷成長。最重要的成長要素之一是全球心血管疾病 (CVD) 和中風的負擔，它們仍然是全球主要死亡原因。隨著醫療保健系統專注於早期檢測、預防和個人化治療方法，對靈敏的心臟生物標記和快速中風診斷的需求正在加速成長。

另一個關鍵促進因素是人口老化，這導致阿茲海默症和帕金森氏症等神經退化性疾病的發生率不斷上升。隨著早期發現和介入成為優先事項，基於血液生物標記、基因篩檢和人工智慧神經影像的體外診斷 (IVD) 解決方案正在蓬勃發展。

市場成長也得益於照護現場(POC) 檢測和分散式診斷的日益普及。從醫院實驗室檢測到可攜式快速診斷解決方案的轉變，使得決策速度更快、患者分診更精準，並能更好地管理急性心臟疾病和神經系統疾病。隨著急診、初級保健和家庭診斷的普及，IVD 製造商正在投資緊湊、易用且高靈敏度的即時診斷 (POC) 檢測平台。

體外診斷（IVD）主導的精準醫療的監管和報銷支持也是影響市場成長的關鍵因素。各國政府和醫療機構正在推廣生物標記主導的治療策略、遺傳性疾病的基因檢測以及人工智慧整合診斷，以最佳化患者治療效果並降低醫療成本。此外，對數位醫療技術和遠端患者監護的投資不斷增加，也推動了人工智慧輔助心臟和神經系統診斷的創新。

部分

產品類型（儀器、試劑和耗材、軟體和服務）、技術（免疫檢測測定、分子診斷、血液學、其他）、最終用戶（醫院、臨床實驗室、其他）

受訪公司範例

• Abbott Laboratories
• Agilent Technologies
• AliveCor
• Becton, Dickinson and Company（BD）
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• DiaSorin SpA
• Hologic Inc.
• LivaNova
• Medtronic
• Mindray Medical International Limited
• Ortho Clinical Diagnostics
• PerkinElmer Inc.
• QIAGEN NV
• Roche Diagnostics
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

人工智慧整合

我們正在利用有效的專家內容和人工智慧工具來改變市場和競爭情報。

Global Industry Analysts 沒有查詢通用的 LLM 或特定產業的SLM，而是建立了一個從世界各地的專家收集的內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地以及進出口情況（成品和原始OEM）預測其競爭地位的變化。這種複雜多變的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 競賽

Global IVD in Cardiology and Neurology Market to Reach US$27.8 Billion by 2030

The global market for IVD in Cardiology and Neurology estimated at US$17.3 Billion in the year 2024, is expected to reach US$27.8 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$17.0 Billion by the end of the analysis period. Growth in the Reagents & Consumables segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.7 Billion While China is Forecast to Grow at 13.1% CAGR

The IVD in Cardiology and Neurology market in the U.S. is estimated at US$4.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.1 Billion by the year 2030 trailing a CAGR of 13.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

IVD in Cardiology and Neurology Market - Key Trends & Drivers Summarized

In-vitro diagnostics (IVD) in cardiology and neurology is rapidly evolving, enabling early disease detection, risk assessment, and personalized treatment strategies. As cardiovascular and neurological disorders continue to be leading causes of mortality and disability worldwide, IVD technologies are playing a crucial role in improving patient outcomes. Advances in biomarker-based testing, molecular diagnostics, point-of-care (POC) testing, and digital health integration are driving innovation in this sector.

With the rising prevalence of heart disease, stroke, neurodegenerative disorders, and cognitive impairments, healthcare providers and researchers are increasingly relying on IVD solutions for accurate diagnosis, disease monitoring, and therapy optimization. The demand for high-sensitivity cardiac and neurological biomarkers, AI-driven diagnostics, and rapid testing solutions is fueling market growth and transforming clinical decision-making.

How Are Technological Advancements Enhancing IVD in Cardiology?

The field of cardiac in-vitro diagnostics has witnessed groundbreaking advancements, particularly in high-sensitivity assays, point-of-care cardiac biomarker testing, and molecular diagnostics. One of the most significant innovations is the development of high-sensitivity cardiac troponin (hs-cTn) tests, which enable the early detection of myocardial infarction (MI) and acute coronary syndrome (ACS). These ultrasensitive assays detect minute changes in cardiac troponin levels, allowing for earlier intervention, improved risk stratification, and reduced hospital admissions.

Another major breakthrough is the integration of multi-biomarker panels for cardiovascular disease risk assessment. Traditionally, lipid profiles (LDL, HDL, total cholesterol, and triglycerides) were the standard for evaluating cardiovascular health. However, modern IVD solutions now incorporate additional biomarkers such as high-sensitivity C-reactive protein (hs-CRP), natriuretic peptides (BNP/NT-proBNP), and myeloperoxidase (MPO) to provide comprehensive cardiovascular risk insights. These advanced biomarker assays are enabling personalized preventive strategies and early-stage cardiovascular disease (CVD) intervention.

The expansion of point-of-care (POC) testing for cardiac markers is another critical trend. Portable, rapid, and handheld POC analyzers now allow for real-time troponin, D-dimer, and BNP testing in emergency rooms, ambulances, and primary care settings. This has significantly improved early triage decisions, reduced turnaround times, and enhanced pre-hospital cardiac event management. Additionally, the rise of wearable biosensors and remote cardiac monitoring devices is enabling continuous cardiac health tracking, leading to proactive interventions and reduced hospitalizations for heart failure and arrhythmias.

Furthermore, molecular and genetic testing for inherited cardiovascular conditions is transforming disease prevention and management. Genetic screening for conditions such as familial hypercholesterolemia (FH), hypertrophic cardiomyopathy (HCM), and long QT syndrome (LQTS) is becoming more accessible, allowing early identification of at-risk individuals and targeted lifestyle or pharmacological interventions. The integration of AI-driven ECG interpretation and digital pathology is also advancing automated CVD diagnosis and prognosis prediction.

What Market Trends Are Driving IVD in Neurology?

The field of neurological diagnostics is undergoing rapid transformation, fueled by the increasing burden of neurodegenerative diseases, stroke, and cognitive disorders. One of the most significant trends is the development of blood-based biomarkers for Alzheimer’s disease (AD) and Parkinson’s disease (PD). Traditionally, the diagnosis of Alzheimer’s relied on cerebrospinal fluid (CSF) analysis or PET imaging, both of which are invasive and expensive. However, recent advancements in plasma-based assays for beta-amyloid (Aβ42/Aβ40 ratio), tau proteins (pTau-181, pTau-217), and neurofilament light chain (NfL) have enabled non-invasive and scalable screening for Alzheimer’s and other neurodegenerative diseases.

Another major trend is the expansion of molecular diagnostics in neurology, particularly in genetic testing for neurodevelopmental disorders, epilepsy, and neuromuscular conditions. Advances in next-generation sequencing (NGS) and CRISPR-based diagnostics are enabling early detection of genetic mutations linked to conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and hereditary ataxias. These precision diagnostic tools are facilitating personalized treatment selection, early interventions, and targeted gene therapies.

The rise of IVD solutions for stroke diagnosis and management is also driving market growth. Traditionally, stroke diagnosis relied on neuroimaging (CT, MRI); however, the introduction of stroke biomarker panels, including glial fibrillary acidic protein (GFAP), S100B, and D-dimer, is enhancing early stroke detection and differentiation between ischemic and hemorrhagic strokes. POC blood-based stroke tests are emerging as a game-changer for pre-hospital stroke assessment, allowing for rapid intervention and better patient outcomes.

Additionally, the growing integration of AI-driven neurodiagnostics, digital biomarkers, and remote monitoring is transforming neurological disease detection and progression tracking. AI-powered analysis of EEG, MRI, and speech patterns is improving the diagnosis of epilepsy, dementia, and movement disorders, while wearable neurotechnology is enabling real-time neuromonitoring for Parkinson’s, MS, and post-stroke rehabilitation.

What Is Driving the Growth of IVD in Cardiology and Neurology?

The IVD market in cardiology and neurology is expanding due to several key growth drivers, including the rising prevalence of cardiovascular and neurodegenerative diseases, advancements in biomarker discovery, and the growing demand for non-invasive diagnostics. One of the most significant growth drivers is the global burden of CVD and stroke, which remain the leading causes of death worldwide. As healthcare systems focus on early detection, prevention, and personalized treatment approaches, the demand for high-sensitivity cardiac biomarkers and rapid stroke diagnostics is accelerating.

Another critical driver is the aging population, which is contributing to the increased incidence of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. With early-stage detection and intervention becoming a priority, IVD solutions based on blood-based biomarkers, genetic screening, and AI-driven neuroimaging analysis are gaining traction.

The increasing adoption of point-of-care (POC) testing and decentralized diagnostics is also fueling market growth. The shift from hospital-based laboratory testing to portable, rapid diagnostic solutions is enabling quicker decision-making, improved patient triage, and better management of acute cardiac and neurological conditions. As emergency medicine, primary care, and home-based diagnostics expand, IVD manufacturers are investing in compact, user-friendly, and highly sensitive POC testing platforms.

Regulatory and reimbursement support for IVD-driven precision medicine is another major factor influencing market growth. Governments and healthcare agencies are promoting biomarker-driven treatment strategies, genetic testing for hereditary conditions, and AI-integrated diagnostics to optimize patient outcomes and reduce healthcare costs. Additionally, the rising investments in digital health technologies and remote patient monitoring are driving innovation in AI-powered cardiac and neurological diagnostics.

SCOPE OF STUDY:

The report analyzes the IVD in Cardiology and Neurology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Instruments, Reagents & Consumables, Software & Services); Technology (Immunoassays, Molecular Diagnostics, Hematology, Others); End-Use (Hospitals, Clinical Laboratories, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Agilent Technologies
• AliveCor
• Becton, Dickinson and Company (BD)
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• Hologic Inc.
• LivaNova
• Medtronic
• Mindray Medical International Limited
• Ortho Clinical Diagnostics
• PerkinElmer Inc.
• QIAGEN N.V.
• Roche Diagnostics
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • IVD in Cardiology and Neurology - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Cardiovascular and Neurodegenerative Disorders Drives Demand for IVD Biomarkers
  • OEM Focus on Early Diagnosis and Risk Stratification Supports Adoption of Specialized IVD Panels
  • Growing Awareness of Stroke and Heart Attack Prevention Boosts Demand for Rapid Testing in Emergency Settings
  • Expansion of Point-of-Care Testing Capabilities Enhances IVD Use in Pre-Hospital and Critical Care Scenarios
  • Increased Investment in High-Sensitivity Troponin and NT-proBNP Assays Fuels Cardiac Test Innovation
  • OEM Innovation in Multi-Biomarker Panels Enables Comprehensive Cardiometabolic and Neuro Panel Testing
  • Integration of IVD With Imaging and EHR Systems Supports Clinical Decision-Making in Cardiology and Neurology
  • Rising Demand for Cost-Effective Stroke Risk Screening Tools Drives Expansion of Blood-Based Diagnostics
  • Expansion of Telecardiology and Teleneurology Services Fuels Need for Decentralized IVD Testing Platforms
  • Growth in Chronic Care Management Models Supports Regular Monitoring of Cardiac and Neurological Biomarkers
  • OEM Development of At-Home and Wearable IVD Devices Enhances Access to Long-Term Disease Monitoring
  • Aging Global Population and Increased Dementia Screening Drive Market for Alzheimers-Related Biomarkers
  • Rising Use of Genetic and Proteomic Testing in Neurology Drives Integration of IVD in Precision Medicine
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World IVD in Cardiology and Neurology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for IVD in Cardiology and Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Clinical Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• JAPAN
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• CHINA
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• EUROPE
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for IVD in Cardiology and Neurology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• FRANCE
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• GERMANY
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• INDIA
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for IVD in Cardiology and Neurology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for IVD in Cardiology and Neurology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• AFRICA
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030

IV. COMPETITION